arrow
S

Sam S. Chang

nyu ibd center
H指数:64
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease

老年炎症性肠病患者中乌司奴单抗和维多珠单抗的安全性与有效性

2025-09-160
PRE
Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors

接受免疫检查点抑制剂治疗后,转移性及局部晚期肾细胞癌患者延迟性肾切除术的临床与病理结局

2025-04-040
OA
Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
2024-05-0113
OA
Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

KRAS突变型胰腺导管腺癌 (PDAC) 和非小细胞肺癌 (NSCLC) 患者的第一类RAS选择性三复合物RAS多 (ON) 抑制剂RMC-6236的初步临床活性

2023-10-0143
OAAI